Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Boehringer Ingelheim: Clinical Trials & FDA Approval Profile

Boehringer Ingelheim (Ingelheim, DE / Ridgefield, CT) sponsors 139 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 45 active protocols (28 recruiting now), 70 completed protocols, and 54 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)17.3%
Median Closed Enrollment vs National (145 pts)156 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Boehringer Ingelheim
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)139
Active Pipeline (Recruiting Now)45 (28)
Completed vs Stopped Early70 / 24 (17.3%)
Median Closed Actual Enrollment156 participants
Physical Hospital Site Disclosure99.9% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals54 (6 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Boehringer Ingelheim
Hospital Research SiteLocationShared Protocols
UZ LeuvenLeuven, Flemish Brabant43
Hospital Universitari Vall d'HebronBarcelona38
Seoul National University HospitalSeoul33

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Boehringer Ingelheim
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07497087A Study to Test Whether Nerandomilast Helps People With Systemic SclerosisPhase IIIRECRUITING
NCT07195695Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2Phase IIIRECRUITING
NCT07540988FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease ProgressionPhase IIIRECRUITING
NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisPhase IIIRECRUITING
NCT07325526A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated SteatohePhase IIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Boehringer Ingelheim Interactive Dossier, benchmark peers in Endocrinology, Obesity, and Metabolic, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI